Effect of Xinjiang UyghurVernonia anthelminticaWilld Injection Treatment with Silicosis Fibrosis

Abstract

Objective. To observe the curative effect of VAWI on Xinjiang Uygur patients with silicosis fibrosis. Methods. After we diagnosed the 40 patients with the first phase of silicosis, we randomly divided them into two groups: the basic treatment group (group A, n = 20) and the VAWI group (group B, n = 20). At the same time, we selected the age-matched healthy patients (n = 20). We applied the combined protein chip with SELDI-TOF-MS to carry out the serum analysis. The data were analyzed throughout data preprocessing, difference in PEAK screening, hierarchical cluster analysis, and Principal Component Analysis (PCA). We built decision tree model and predict the difference between the PEAK corresponding proteins. Results. The proteins peaks corresponding to name, predicted protein, and gene name were as follows: M2001_69, amyloid beta a4 protein, APP, and M2017_02, amyloid beta a4 protein, APP. The different expression of proteins in patients with silicosis was found before and after with VAWI treatment. The predicted proteins were as follows: M1982_50, amyloid beta a4 protein, APP; M3164_50, fibrinogen alpha chain frag, FGA; M3379_28, fibrinogen alpha chain frag, FGA; and so on. Conclusion. VAWI presented curative effect on patients with silicosis fibrosis via the alternation of proteins expression in serum.

Baccharoides anthelmintica (L.) Moench: A Review on Ethnomedicinal, Phytochemical, Pharmacological and Toxicological Profile

“…In addition to a clinical study conducted with 40 other patients facing the problem of silicosis fibrosis, an injection of XUM was administered. The XUM showed a therapeutic effect through the appearance of alternate proteins (amyloid beta a4 protein, M1982_50, and M2017_02) [185–187] . Therefore, studies support the use of B. anthelmintica in the treatment of respiratory diseases.…”

“…The XUM showed a therapeutic effect through the appearance of alternate proteins (amyloid beta a4 protein, M1982_50, and M2017_02). [185][186][187] Therefore, studies support the use of B. anthelmintica in the treatment of respiratory diseases. Clinical trials often serve as authentic investigations for ethnomedical claims and determine the safe and effective treatments for patients.…”